Early stages of mesothelioma, screening and biomarkers

Recent Results in Cancer Research

Volumn 189, Issue , 2011, Pages 169-193

  Klebe, Sonja ^a   Henderson, Douglas W ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AQUAPORIN; BORTEZOMIB; CA 125 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; GLUCOSE TRANSPORTER 1; GLYCOPROTEIN P; MEGAKARYOCYTE POTENTIATING FACTOR; NERVE CELL ADHESION MOLECULE; OSTEOPONTIN; PROTEIN BCL 2; PROTEIN P53; SOLUBLE MESOTHELIN RELATED PROTEIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; ASBESTOSIS; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER MORPHOLOGY; CANCER SCREENING; CANCER STAGING; CELL HYPERPLASIA; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENE LOSS; GENE OVEREXPRESSION; GENETIC GAIN; HISTOPATHOLOGY; HUMAN; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; NONHUMAN; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; THORAX RADIOGRAPHY; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD56; AQUAPORINS; ASBESTOS; CA-125 ANTIGEN; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GLUCOSE TRANSPORTER TYPE 1; GLYCOPROTEINS; GPI-LINKED PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MESOTHELIOMA; MUCIN-1; NEOPLASM STAGING; OSTEOPONTIN; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 79955027939     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10862-4_10     Document Type: Article

References (195)

1. Acurio A, Arif Q, Gattuso P et al (2008) The value of immunohistochemical markers in differentiating benign from malignant mesothelial lesions. Mod Pathol 21(1S):334A
2. Afify A, Zhou H, Howell L, Paulino AF (2005) Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol 49(3):621-626 (Pubitemid 41667079)
3. Agre P, Kozono D (2003) Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett 555(1):72-78 (Pubitemid 37431100)
4. Amiry-Moghaddam M, Frydenlund DS, Ottersen OP (2004) Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport. Neuroscience 129(4):999-1010 (Pubitemid 39556251)
5. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR (2002) Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 40(3):237-244 (Pubitemid 34227114)
6. Attanoos RL, Griffin A, Gibbs AR (2003) The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43(3):231-238 (Pubitemid 37115056)
7. Bao LH, Sakaguchi H, Fujimoto J, Tamaya T (2007) Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 14(3):373-381 (Pubitemid 46855418)
8. Baratti D, Kusamura S, Martinetti A et al (2007) Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 14(11):500-508 (Pubitemid 46175294)
9. Baruch AC, Wang H, Staerkel GA et al (2007) Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol 35(3):143-147 (Pubitemid 46355345)
10. Bateman AC, Al-Talib RK, Newman T et al (1997) Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1. Histopathology 30(1):49-56 (Pubitemid 27072448)
11. Battifora H, McCaughey W (1995) Tumors of the serosal membranes, Third series, AFIP Atlas of Tumor Pathology. American Registry of Pathology, Washington, DC
12. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145(5):1036-1040 (Pubitemid 24345651)
13. Bergeret A, De Terrasson FG (1999) Social impact of screening and of medical surveillance on people exposed to asbestos. Rev Mal Respir 16(6pt2):1327-1331 (Pubitemid 30014282)
14. Beyer HL, Geschwindt RD, Glover CL et al (2007) MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 53(4):666-672 (Pubitemid 46580236)
15. Bloch O, Papadopoulos MC, Manley GT, Verkman AS (2005) Aquaporin-4 gene deletion in mice increases focal edema associated with staphylococcal brain abscess. J Neurochem 95(1):254-262 (Pubitemid 41384443)
16. Bolen JW, Hammar SP, McNutt MA (1986) Reactive and neoplastic serosal tissue: a light-microscopic, ultrastructural, and immunocy-tochemical study. Am J Surg Pathol 10(1):34-47 (Pubitemid 16108565)
17. Bolen JW, Hammar SP, McNutt MA (1987) Serosal tissue: reactive tissue as a model for understanding mesotheliomas. Ultrastruct Pathol 11(2-3):251-262 (Pubitemid 17076965)
18. Borgnia M, Nielsen S, Engel A, Agre P (1999) Cellular and molecular biology of the aquaporin water channels. Annu Rev Biochem 68: 425-458 (Pubitemid 29449199)
19. Borok Z, Verkman AS (2002) Lung edema clearance: 20 years of progress: invited review: role of aquaporin water channels in fluid transport in lung and airways. J Appl Physiol 93(6): 2199-2206 (Pubitemid 35379348)
20. Brambilla E, Cagle PT, Churg AM, Colby TV, Gibbs AR, Hammar SP, Hasleton PS, Henderson DW, Inai K, Praet M, Roggli VL, Travis WD, Vignaud JM (2006) International Mesothelioma Panel. In: Galateau-Sallé F (ed) Pathology of malignant mesothelioma. Springer, London
21. Brauer C, Baandrup U, Jacobsen P et al (2009) Screening for asbestos-related conditions. Ugeskr Laeger 171:433-436
22. British Thoracic Society Standards of Care Committee (2007) BTS statement on malignant mesothelioma in the UK, 2007. Thorax 62(Suppl 2):ii1-ii19
23. Cagle PT, Brown RW, Lebovitz RM (1994) P53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 25(5):443-448
24. Ceresoli GL, Chiti A, Zucali PA et al (2007) Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev 33(6):533-541 (Pubitemid 47355343)
25. Chen Y, Tachibana O, Oda M et al (2006) Increased expression of aquaporin 1 in human hemangioblastomas and its correlation with cyst formation. J Neurooncol 80(3):219-225 (Pubitemid 44782898)
26. Churg A, Colby TV, Cagle P et al (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183-1200
27. Churg A, Cagle PT, Roggli VL (2006) Tumors of the serosal membranes. American Registry of Pathology/Armed Forces Institute of Pathology, Washington, DC
28. Clapp C, de la EG Martinez (2006) Aquaporin-1: a novel promoter of tumor angiogenesis. Trends Endocrinol Metab 17(1):1-2 (Pubitemid 43031376)
29. Creaney J, Robinson BW (2005) Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 19:1025-1040 (Pubitemid 41736040)
30. Creaney J, Robinson BW (2009) Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 15(6):366-370
31. Creaney J, Christansen H, Lake R et al (2006) Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 1(1):172-174 (Pubitemid 47164007)
32. Creaney J, Yeoman D, Naumoff L et al (2007) Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 62(7):569-576 (Pubitemid 47056881)
33. Creaney J, Yeoman D, Demelker Y et al (2008) Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3(8):851-857
34. Cury PM, Butcher DN, Corrin B, Nicholson AG (1999) The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189(2):251-257 (Pubitemid 29448921)
35. Das M, Muhlenbruch G, Mahnken AH et al (2007) Asbestos Surveillance Program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. Eur Radiol 17(5):1193-1199 (Pubitemid 46691948)
36. Devuyst O, Ni J (2006) Aquaporin-1 in the peritoneal membrane: implications for water transport across capillaries and peritoneal dialysis. Biochim Biophys Acta 1758(8):1078-1084 (Pubitemid 44373857)
37. Diederich S, Wormanns D, Heindel W (2003) Lung cancer screening with low-dose CT. Eur J Radiol 45(1):2-7 (Pubitemid 36020306)
38. Endo M, Jain RK, Witwer B, Brown D (1999) Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glio-blastomas. Microvasc Res 58(2):89-98 (Pubitemid 29419934)
39. Esposito V, Baldi A, De Luca A et al (1997) P53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res 17(18):733-736 (Pubitemid 27105559)
40. Esteban JM, Yokota S, Husain S, Battifora H (1990) Immunocytochemical profile of benign and carcinomatous effusions: a practical approach to difficult diagnosis. Am J Clin Pathol 94(6):698-705
41. Eto M, Kodama S, Nomi N et al (2007) Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx 34(3):343-346 (Pubitemid 46829719)
42. Falleni M, Pellegrini C, Marchetti A et al (2005) Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 48(2):211-216
43. Fasola G, Belvedere O, Aita M et al (2007) Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial - an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 12(10):1215-1224 (Pubitemid 350106352)
44. Fleming MV, Guinee DG Jr, Chu WS et al (1998) Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol 29(1):60-64 (Pubitemid 28049547)
45. Frey AB, Wali A, Pass H, Lonardo F (2007) Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 50(6):720-726 (Pubitemid 46683928)
46. Geeson F, Saadoun S, Papadopoulos M et al (2002) Aquaporin-4 water channel expression in human vasogenic brain oedema. J Anat 200(5):523
47. Goffin E, Combet S, Jamar F et al (1999) Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport. Am J Kidney Dis 33(2):383-388 (Pubitemid 29072245)
48. Gordon GJ, Mani M, Maulik G et al (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549-558
49. Greillier L, Baas P, Welch JJ et al (2008) Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 12(8):375-390 (Pubitemid 352790451)
50. Grigoriu BD, Scherpereel A, Devos P et al (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13:2928-2935 (Pubitemid 46850705)
51. Grigoriu BD, Gregoire M, Chahine B, Scherpereel A (2008) New diagnostic markers for malignant pleural mesothelioma. Bull Cancer 95(2):177-184 (Pubitemid 351341288)
52. Grigoriu BD, Grigoriu C, Chahine B et al (2009) Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 71(1):31-38
53. Haddoub R, Rutzler M, Robin A, Flitsch SL (2009) Design, synthesis and assaying of potential aquaporin inhibitors. Handb Exp Pharmacol 385-402
54. Hammar SP, Henderson DW, Klebe S, Dodson RF (2008) Neoplasms of the pleura. In: Tomashefski JFJ (ed) Dail and Hammar's Pulmonary pathology, chap 43, vol 2, 3rd edn. Springer, New York, pp 558-734
55. Hassan R, Laszik ZG, Lerner M et al (2005) Mesothelin is overexpressed in pancreatobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124(6):838-845 (Pubitemid 41740183)
56. Hassan R, Remaley AT, Sampson ML et al (2006) Detection and quantitation of serum mesothelin, a tumor parker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12(2):447-453 (Pubitemid 43166134)
57. Haylock DN, Nilsson SK (2006) Osteopontin: a bridge between bone and blood. Br J Haematol 134(5):467-474 (Pubitemid 44141712)
58. Hedman M, Arnberg H, Wernlund J et al (2003) Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 23(1B):531-536 (Pubitemid 36358446)
59. Henderson DW, Shilkin KB, Whitaker D et al (1992) The pathology of mesothelioma, including immunohistology and ultrastructure. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D (eds) Malignant mesothelioma. Hemisphere, New York, pp 69-139
60. Henderson DW, Comin CE, Hammar SP et al (1997) Malignant mesothelioma of the pleura: current surgical pathology. In: Corrin B (ed) Pathology of lung tumors. Churchill Livingstone, New York, pp 241-280
61. Henderson DW, Shilkin KB, Whitaker D (1998) Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110(3):397-404 (Pubitemid 28407000)
62. Henschke CI, Yankelevitz DF (2000) Screening for lung cancer. J Thorac Imaging 15(1):21-27 (Pubitemid 30022852)
63. Henschke CI, McCauley DI, Yankelevitz DF et al (1999) Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354(173):99-105 (Pubitemid 29313143)
64. Ho M, Bera TK, Willingham MC et al (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13(5):1571-1575 (Pubitemid 46450449)
65. Hoque MO, Soria JC, Woo J et al (2006) Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol 168(4):1345-1353
66. Huber VJ, Tsujita M, Yamazaki M et al (2007) Identification of arylsulfonamides as Aquaporin 4 inhibitors. Bioorg Med Chem Lett 17(5): 1270-1273 (Pubitemid 46240848)
67. Huber VJ, Tsujita M, Kwee IL, Nakada T (2009) Inhibition of aquaporin 4 by antiepileptic drugs. Bioorg Med Chem 17(1):418-424
68. Huber VJ, Tsujita M, Nakada T (2009) Identification of aquaporin 4 inhibitors using in vitro and in silico methods. Bioorg Med Chem 17(1):411-417
69. Husain AN, Colby TV, Ordonez NG et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133(8):1317-1331
70. Ishibashi K, Hara S, Kondo S (2009) Aquaporin water channels in mammals. Clin Exp Nephrol 13(2):107-117 S. Klebe and D.W. Henderson
71. Isik R, Metintas M, Gibbs AR et al (2001) P53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir Med 95(7):588-593 (Pubitemid 32624524)
72. Ivanov SV, Ivanova AV, Goparaju CM et al (2009) Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382(3):514-518
73. Iwahori K, Osaki T, Serada S et al (2008) Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 62(1):45-54
74. Jarius S, Paul F, Franciotta D et al (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4(4):202-214 (Pubitemid 351516748)
75. Jiang JJ, Bai CX, Hong QY et al (2003) Effect of aquaporin-1 deletion on pleural fluid transport. Acta Pharmacol Sin 24(4):301-305
76. Jiang J, Hu J, Bai C (2003) Role of aquaporin and sodium channel in pleural water movement. Respir Physiol Neurobiol 139(1):83-88 (Pubitemid 37443625)
77. Kato Y, Tsuta K, Seki K et al (2007) Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 20(2): 215-220 (Pubitemid 46422176)
78. Kebapci M, Vardarell E, Adapinar B, Acikalin M (2003) CT findings and serum ca CA125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 13(12):2620-2626 (Pubitemid 37527067)
79. Kim J, Ki SS, Lee SD et al (2006) Elevated levels of osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 101(9):2051-2059 (Pubitemid 44337631)
80. King LS, Agre P (1996) Pathophysiology of the aquaporin water channels. Annu Rev Physiol 58:619-648 (Pubitemid 26106737)
81. King LS, Nielsen S, Agre P (1996) Aquaporin-1 water channel protein in lung: ontogeny, steroidinduced expression, and distribution in rat. J Clin Invest 97(10):2183-2191
82. King LS, Kozono D, Agre P (2004) From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 50:687-698 (Pubitemid 39208179)
83. King J, Thatcher N, Pickering C, Hasleton P (2006) Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histo pathology 49(6):561-568 (Pubitemid 44924287)
84. Knepper MA (1994) The aquaporin family of molecular water channels. Proc Natl Acad Sci USA 91(14):6255-6258 (Pubitemid 24200638)
85. Koskinen K, Rinne JP, Zitting A et al (1996) Screening for asbestos-induced diseases in Finland. Am J Ind Med 30(3):241-251 (Pubitemid 26299958)
86. Koskinen K, Pukkala E, Reijula K, Karjalainen A (2003) Incidence of cancer among the participants of the Finnish Asbestos Screening Campaign. Scand J Work Environ Health 29(1):64-70 (Pubitemid 36231043)
87. Kushitani K, Takeshima Y, Amatya VJ et al (2007) Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 57(4):190-199 (Pubitemid 46279947)
88. Lai KN, Li FK, Lan HY et al (2001) Expression of aquaporin-1 in human peritoneal mesothelial cells and its upregulation by glucose in vitro. J Am Soc Nephrol 12(5):1036-1045 (Pubitemid 32378345)
89. Lantuejoul S, Laverriere MH, Sturm N et al (2000) NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas. Hum Pathol 31(4):415-421 (Pubitemid 30262861)
90. Lauritzen AF (1987) Distinction between cells in serous effusions using a panel of antibodies. Virchows Arch A 411(3):299-304 (Pubitemid 17108321)
91. Lee MD, King LS, Agre P (1997) The aquaporin family of water channel proteins in clinical medicine. Medicine (Baltimore) 76(3):141-156 (Pubitemid 27255818)
92. Leung AN, Muller NL, Miller RR (1990) CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 154(3):487-492 (Pubitemid 20071594)
93. Liakopoulos V, Zarogiannis S, Eleftheriadis T, Stefanidis I (2006) Aquaporin-1 and sodium transport in the peritoneal membrane - need for more research? Kidney Int 70 (9):1663, author reply - 4 (Pubitemid 44607008)
94. Liakopoulos V, Zarogiannis S, Hatzoglou C et al (2006) Inhibition by mercuric chloride of aquaporin-1 in the parietal sheep peritoneum: an electrophysiologic study. Adv Perit Dial 22:7-10
95. Liang Q, Xu SR, Liu W et al (2005) Expressions of aquaporin-1 on peritonea in hepatic cirrhotic rats with ascites [Chin]. Zhonghua Yi Xue Za Zhi 85(15):1027-1030 (Pubitemid 40590349)
96. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D (2008) Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med 132(1):23-28
97. Maeda M, Hino O (2006) Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 56(11): 649-654 (Pubitemid 44570013)
98. Mangano WE, Cagle PT, Churg A et al (1998) The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 110(2): 191-199 (Pubitemid 28357658)
99. Mason MR, Bedrossian CW, Fahey CA (1987) Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 3(3): 215-221
100. Mastrangelo G, Ballarin MN, Bellini E et al (2008) Feasibility of a screening programme for lung cancer in former asbestos workers. Occup Med (Lond) 58(3):175-180
101. Mayall FG, Goddard H, Gibbs AR (1993) The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas. Histopathology 22(4):383-386 (Pubitemid 23159801)
102. Mayall F, Heryet A, Manga D, Kriegeskotten A (1997) P53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 8(1):9-12 (Pubitemid 27107127)
103. Mazal PR, Susani M, Wrba F, Haitel A (2005) Diagnostic significance of aquaporin-1 in liver tumors. Hum Pathol 36(11):1226-1231 (Pubitemid 41540400)
104. Metintas M, Ucgun I, Elbek O et al (2002) Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol 41(1):1-9 (Pubitemid 34002983)
105. Miettinen M, Sarlomo-Rikala M (2003) Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 27(2):150-158 (Pubitemid 36152223)
106. Mishima R, Takeshima F, Sawai T et al (2007) High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 41(2):167-172 (Pubitemid 46148658)
107. Misu T, Fujihara K, Nakamura M et al (2006) Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 209(3):269-275 (Pubitemid 43905560)
108. Misu T, Fujihara K, Itoyama Y (2008) Neuromyelitis optica and anti-aquaporin 4 antibody - an overview. Brain Nerve 60(5): 527-537 (Pubitemid 351753984)
109. Mullick SS, Green LK, Ramzy I et al (1996) P53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells. Acta Cytol 40(5):855-860 (Pubitemid 26322332)
110. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC (1998) Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 275(1pt1):L165-L171
111. Navratil E, Gaulard P, Kanavaros P et al (1995) Expression of the bcl-2 protein in B cell lymphomas arising from mucosa associated lymphoid tissue. J Clin Pathol 48(1):18-21
112. Nishino T, Devuyst O (2008) Clinical application of aquaporin research: aquaporin-1 in the peritoneal membrane. Pflugers Arch 456(4): 721-727
113. Onda M, Nagata S, Ho M et al (2006) Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12(14):4225-4231
114. Ordonez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16(3):192-197 (Pubitemid 36337423)
115. Oshio K, Binder DK, Bollen A et al (2003) Aquaporin-1 expression in human glial tumors suggests a potential novel therapeutic target for tumor-associated edema. Acta Neurochir Suppl 86:499-502
116. Oshio K, Binder DK, Liang Y et al (2005) Expression of the aquaporin-1 water channel in human glial tumors. Neurosurgery 56(2): 375-381
117. Papadopoulos MC, Verkman AS (2005) Aquaporin-4 gene disruption in mice reduces brain swelling and mortality in pneumococcal meningitis. J Biol Chem 280(14):13906-13912 (Pubitemid 40517291)
118. Papadopoulos MC, Verkman AS (2007) Aquaporin-4 and brain edema. Pediatr Nephrol 22(6):778-784 (Pubitemid 46629610)
119. Papadopoulos MC, Verkman AS (2008) Potential utility of aquaporin modulators for therapy of brain disorders. Prog Brain Res 170:589-601 (Pubitemid 352024380)
120. Papadopoulos MC, Manley GT, Krishna S, Verkman AS (2004) Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 18(11):1291-1293 (Pubitemid 39561580)
121. Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18(2): 425-433
122. Park EK, Sandrini A, Yates DH et al (2008) Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study: the Dust Diseases Board cohort study. Am J Respir Crit Care Med 178(8):832-837
123. Pass HI, Carbone M (2009) Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21(2):97-104
124. Pass HI, Lott D, Lonardo F et al (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15):1564-1573 (Pubitemid 41434635)
125. Pittock SJ, Lennon VA (2008) Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65(5):629-632 (Pubitemid 351679657)
126. Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63(7):964-968 (Pubitemid 44036298)
127. Qiao YL, Tockman MS, Li L et al (1997) A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China. Cancer Epidemiol Biomarkers Prev 6(11):893-900 (Pubitemid 27481637)
128. Ramael M, Lemmens G, Eerdekens C et al (1992) Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168(4):371-375 (Pubitemid 23013253)
129. Ramael M, van den Bossche J, Buysse C et al (1992) Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J Pathol 167(1):5-8
130. Ray M, Kindler HL (2009) Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136:888-896
131. Robinson BW, Creaney J, Lake R et al (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396):1612-1616 (Pubitemid 37443528)
132. Robinson BW, Creaney J, Lake R et al (2005) Soluble mesothelin-related protein: a blood test for mesothelioma. Lung Cancer 49(Suppl 1):S109-S111 (Pubitemid 40798859)
133. Rump A, Morikawa Y, Tanaka M et al (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279(10):9190-9198 (Pubitemid 38295982)
134. Saad RS, Cho P, Liu YL, Silverman JF (2005) The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 32(3):156-159 (Pubitemid 40256265)
135. Saadoun S, Papadopoulos MC (2009) Aquaporin-4 in brain and spinal cord oedema. Neuroscience 161(3):764-772
136. Saadoun S, Papadopoulos M, Bell B et al (2002) The aquaporin-4 water channel and brain tumour oedema. J Anat 200(5):528
137. Saadoun S, Papadopoulos MC, Davies DC et al (2002) Increased aquaporin 1 water channel expression in human brain tumours. Br J Cancer 87(6):621-623
138. Saikali P, Cayrol R, Vincent T (2009) Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 9(2):132-135
139. Sapede C, Gauvrit A, Barbieux I et al (2008) Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 99(3):590-594 (Pubitemid 351228578)
140. Scherpereel A, Lee YC (2007) Biomarkers for mesothelioma. Curr Opin Pulm Med 13(4): 339-443
141. Scherpereel A, Grigoriu B, Conti M et al (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173(10): 1155-1160 (Pubitemid 43726897)
142. Scherpereel A, Astoul P, Baas P et al (2009) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural Mesothelioma. Eur Respir J 35(3):479-495
143. Schneider J, Presek P, Braun A et al (1999) P53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer 80(12):1987-1994 (Pubitemid 29391286)
144. Segal A, Whitaker D, Henderson D, Shilkin K (2002) Pathology of mesothelioma. In: Robinson BWS, Chahinian AP (eds) Mesothelioma. Martin Dunitz, London, pp 143-184
145. Segers K, Ramael M, Singh SK et al (1994) Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 424(6):631-634 (Pubitemid 24245334)
146. Segers K, Kumar-Singh S, Weyler J et al (1996) Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study. J Cancer Res Clin Oncol 122(10):619-624 (Pubitemid 26325589)
147. Shen J, Pinkus GS, Deshpande V, Cibas ES (2009) Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 131(4):516-523
148. Shiomi K, Miyamoto H, Segawa T et al (2006) Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97(6):928-932 (Pubitemid 44151275)
149. Shiomi K, Hagiwara Y, Sonoue K et al (2008) Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 14(5):1431-1437 (Pubitemid 351413926)
150. Silverman JF, Nance K, Phillips B, Norris HT (1987) The use of immunoperoxidase panels for the cytologic diagnosis of malignancy in serous effusions. Diagn Cytopathol 3(2):134-140
151. Simon F, Johnen G, Krismann M, Muller KM (2005) Chromosomal alterations in early stages of malignant mesotheliomas. Virchows Arch 447(4):762-767 (Pubitemid 41571193)
152. Soini Y, Jarvinen K, Kaarteenaho-Wiik R, Kinnula V (2001) The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12(9):1239-1245 (Pubitemid 32994751)
153. Sone S, Takashima S, Li F et al (1998) Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351(9111):1242-1245 (Pubitemid 28181964)
154. Song Y, Yang B, Matthay MA et al (2000) Role of aquaporin water channels in pleural fluid dynamics. Am J Physiol Cell Physiol 279(6):C1744-C1750
155. Szeto CC, Lai KB, Chow KM et al (2005) The relationship between peritoneal transport characteristics and messenger RNA expression of aquaporin in the peritoneal dialysis effluent of CAPD patients. J Nephrol 18(2):197-203
156. Takagi M, Tanaka K, Suzuki T et al (2009) Anti-aquaporin-4 antibody-positive optic neuritis. Acta Ophthalmol 87(5):562-566
157. Takahashi T, Fujihara K, Nakashima I et al (2006) Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210(4):307-313 (Pubitemid 44883971)
158. Tan WL, Wong JH, Liew D, Ng IH (2004) Aquaporin-4 is correlated with peri-tumoural oedema in meningiomas. Ann Acad Med Singapore 33(5 Suppl):S87-S89
159. Tanaka K (2008) Anti-aquaporin 4-antibody detection system. Nippon Rinsho 66(6): 1093-1097
160. Tani T, Sakimura K, Tsujita M et al (2009) Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J Neuroimmunol 211(1-2):110-113
161. Tanimura Y, Hiroaki Y, Fujiyoshi Y (2009) Acetazolamide reversibly inhibits water conduction by aquaporin-4. J Struct Biol 166(1): 16-21
162. Tiitola M, Kivisaari L, Huuskonen MS et al (2002) Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer 35(1):17-22 (Pubitemid 34028086)
163. Uzawa A, Mori M, Iwai Y et al (2009) Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci 287(1-2):105-107
164. van der Kwast TH, Versnel MA, Delahaye M et al (1988) Expression of epithelial membrane antigen on malignant mesothelioma cells: an immunocytochemical and immunoelectron microscopic study. Acta Cytol 32(2):169-174 (Pubitemid 18091144)
165. van Meerbeeck J P, Hillerdal G (2008) Screening for mesothelioma: more harm than good? Am J Respir Crit Care Med 178(8): 781-782
166. Verkman AS (1998) Role of aquaporin water channels in kidney and lung. Am J Med Sci 316(5):310-320 (Pubitemid 28525028)
167. Verkman AS (1999) Lessons on renal physiology from transgenic mice lacking aquaporin water channels. J Am Soc Nephrol 10(5): 1126-1135 (Pubitemid 29203101)
168. Verkman AS (2001) Applications of aquaporin inhibitors. Drug News Perspect 14(7):412-420 (Pubitemid 33140707)
169. Verkman AS (2002) Physiological importance of aquaporin water channels. Ann Med 34(3): 192-200 (Pubitemid 34804192)
170. Verkman AS (2002) Renal concentrating and diluting function in deficiency of specific aquaporin genes. Exp Nephrol 10(4):235-240 (Pubitemid 34827780)
171. Verkman AS, Matthay MA, Song Y (2000) Aquaporin water channels and lung physiology. Am J Physiol Lung Cell Mol Physiol 278(5):L867-L879 (Pubitemid 30351041)
172. Verkman AS, Yang B, Song Y et al (2000) Role of water channels in fluid transport studied by phenotype analysis of aquaporin knockout mice. Exp Physiol 85. Spec No: 233S-241S
173. Vordermark D, Said HM, Katzer A et al (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 15(6):207-212
174. Walts AE, Said JW, Shintaku IP (1987) Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: immunocytochemical and ultrastructural localization in benign and malignant cells. Diagn Cytopathol 3(1):41-49
175. Waters P, Vincent A (2008) Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 15(3):99-105
176. Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65(7):913-919 (Pubitemid 352008474)
177. Whitaker D (1983) The mesothelium of the rat and its response to injury. Ph.D. thesis, The University of Western Australia, Perth
178. Whitaker D, Papadimitriou JM (1985) Mesothelial healing: morphological and kinetic investigations. J Pathol 145(2):159-175 (Pubitemid 15138587)
179. Whitaker D, Sterrett G, Shilkin K (1989) Early diagnosis of malignant mesothelioma: the contribution of effusion and fine needle aspiration cytology and ancillary techniques. In: Peters GA, Peters BJ (eds) Asbestos disease update March 1989. A special supplement to the sourcebook on Asbestos diseases: medical, legal, and engineering aspects. Garland Law Publishing, New York, pp 73-112
180. Whitaker D, Henderson DW, Shilkin KB (1992) The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9(2):151-161
181. Whitaker D, Manning LS, Robinson BW, Shilkin KB (1992) The pathobiology of the mesothelium. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D (eds) Malignant mesothelioma. Hemisphere, New York, pp 25-68
182. Whitaker D, Shilkin KB, Sterrett GF (1992) Cytological appearances of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D (eds) Malignant mesothelioma. Hemisphere, New York, pp 167-182
183. Wolanski KD, Whitaker D, Shilkin KB, Henderson DW (1998) The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82(3):583-590 (Pubitemid 28112999)
184. Wu M, Yuan S, Szporn AH et al (2005) Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 18(12):1618-1622 (Pubitemid 41670662)
185. Wu CY, Wu MS, Chiang EP et al (2006) Elevated plasma osteopontin associated with gastric carcinoma development, invasion and survival. Gut 56(5):782-789
186. Wu M, Sun Y, Li G et al (2007) Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol 128(5):783-787 (Pubitemid 350133989)
187. Xiang Y, Ma B, Li T et al (2004) Acetazolamide inhibits aquaporin-1 protein expression and angiogenesis. Acta Pharmacol Sin 25(6): 812-816 (Pubitemid 38736110)
188. Yaziji H, Battifora H, Barry TS et al (2006) Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 19(4):514-523
189. Yen MJ, Hsu C-Y, Mao T-L et al (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12(3pt1):827-831 (Pubitemid 43259864)
190. Yool AJ, Brokl OH, Pannabecker TL et al (2002) Tetraethylammonium block of water flux in Aquaporin-1 channels expressed in kidney thin limbs of Henle's loop and a kidney-derived cell line. BMC Physiol 2:4
191. Yukutake Y, Hirano Y, Suematsu M, Yasui M (2009) Rapid and reversible inhibition of aquaporin-4 by zinc. Biochemistry 48(51): 12059-12061
192. Zalay Z, Nemeth L, Sugar J (1992) Screening and pathological diagnosis of asbestosis and mesothelioma: a review. J Environ Pathol Toxicol Oncol 11(5-6):317-321 (Pubitemid 23015479)
193. Zhang W, Xie CM, Li ZP (2007) Expression of aquaporin-1 in rat pleural mesothelial cells and its specific inhibition by RNA interference in vitro. Chin Med J (Engl) 120(24): 2278-2283
194. Zheng YY, Lan YP, Tang HF, Zhu SM (2008) Propofol pretreatment attenuates aquaporin-4 over-expression and alleviates cerebral edema after transient focal brain ischemia reperfusion in rats. Anesth Analg 107(6):2009-2016
195. Zhu W, Michael CW (2007) WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 35(6):370-375 (Pubitemid 46835030)